340 related articles for article (PubMed ID: 30574813)
21. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
[TBL] [Abstract][Full Text] [Related]
22. The design of clinical trials to support the switching and alternation of biosimilars.
Faccin F; Tebbey P; Alexander E; Wang X; Cui L; Albuquerque T
Expert Opin Biol Ther; 2016 Dec; 16(12):1445-1453. PubMed ID: 27666115
[TBL] [Abstract][Full Text] [Related]
23. Uptake of rheumatology biosimilars in the absence of forced switching.
Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
[TBL] [Abstract][Full Text] [Related]
24. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
25. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
[TBL] [Abstract][Full Text] [Related]
26. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
[TBL] [Abstract][Full Text] [Related]
27. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
Bakalos G; Zintzaras E
Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
[TBL] [Abstract][Full Text] [Related]
28. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
29. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
31. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
32. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
Danese S; Fiorino G
Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
[TBL] [Abstract][Full Text] [Related]
33. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
34. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice.
Armuzzi A; Bouhnik Y; Cummings F; Bettey M; Pieper B; Kang T
Dig Liver Dis; 2020 Nov; 52(11):1259-1265. PubMed ID: 32601035
[TBL] [Abstract][Full Text] [Related]
35. Biosimilars for the treatment of psoriasis.
Puig L; López-Ferrer A
Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
[No Abstract] [Full Text] [Related]
36. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
38. ABP 501 for the treatment of rheumatoid arthritis.
Pelechas E; Voulgari PV; Drosos AA
Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
[TBL] [Abstract][Full Text] [Related]
39. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
40. Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico.
Mayoral-Zavala A; Esquivel-Aguilar A; Del Real-Calzada CM; Gutiérrez-Grobe Y; Ramos-García J; Rocha-Ramírez JL; Rojas-Illanes MF; Rubio-Martínez B; Sánchez-Chávez X; Yamamoto-Furusho JK;
Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):414-423. PubMed ID: 29685744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
